11 Most Shorted Stocks to Buy According to Analysts

Page 3 of 11

9. ImmunityBio, Inc. (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the most shorted stocks to buy according to analysts. H.C. Wainwright maintained a Buy rating for ImmunityBio, Inc. (NASDAQ:IBRX) and increased its price target to $15 from $10 on February 23. According to the firm, following ANKTIVA’s U.S. introduction in 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported that the medication brought in $113 million.

The company also saw a 750% increase in unit sales, with Q4 revenue of $38.3 million, up 20% from the third quarter. Moreover, ImmunityBio, Inc. (NASDAQ:IBRX) has broadened its global reach by teaming with Biopharma and Cigalah Healthcare to commercialize ANKTIVA in Saudi Arabia and the MENA area, after regulatory clearance from the Saudi Food and Drug Authority.

At the same time, ImmunityBio, Inc. (NASDAQ:IBRX) is conducting randomized studies in BCG-naïve non-muscle-invasive bladder cancer. The company plans to submit a Biologics License Application in the fourth quarter of 2026.

ImmunityBio, Inc. (NASDAQ:IBRX) is a U.S. biotechnology company developing next‑generation immunotherapies and vaccines that enhance the natural immune system to fight cancers and infectious diseases.

Page 3 of 11